Literature DB >> 25120824

A case of blastic plasmacytoid dendritic cell neoplasm with ecchymotic lesions on the whole body.

Xiao-Bin Cui1, Jing Jin1, Xue-Lian Pang1, Su Li1, Chun-Xia Liu1, Ting-Ting Li1, Hao Peng1, Shu-Mao Zhang1, Li Li2, Wei-Hua Liang2, Yun-Zhao Chen1, Feng Li1.   

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) derived from plasmacytoid dendritic cell precursors is a very rare, and characterized by cutaneous and bone marrow involvement and leukemic spread. The neoplasm presents with an aggressive behavior, and the clinical findings include cytopenia, particularly thrombocytopenia. The tumor cells are negative for antigens of T- and B- cell lines. However, these cells express CD4, CD56 and CD123, which are markers of plasmacytoid dendritic cells, and negative for Epstein-Barr virus (EBV). From this point of view, a 71-year-old man who was initially found to have a cutaneous mass on his face and thorax was reported here, and initially was diagnosed as "eczema". The skin rashes then became aggravated on a trial of low dose topical corticosteroid for 2 months. According to skin biopsy, the tumor cells reveal an immature blastic appearance and positive for CD4 and CD56, negative for CD3, CD20, indicating a diagnosis of BPDCN. Here, we report the dismal course of a patient with BPDCN without accepting further therapy, and only survived 3 months.

Entities:  

Keywords:  BPDCN; Blastic plasmacytoid dendritic cell neoplasm; neoplasm

Mesh:

Substances:

Year:  2014        PMID: 25120824      PMCID: PMC4129059     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  Identification of a leukemic counterpart of the plasmacytoid dendritic cells.

Authors:  L Chaperot; N Bendriss; O Manches; R Gressin; M Maynadie; F Trimoreau; H Orfeuvre; B Corront; J Feuillard; J J Sotto; J C Bensa; F Brière; J Plumas; M C Jacob
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

2.  A case of cutaneous blastic plasmacytoid dendritic cell neoplasm.

Authors:  Ruzeng Xue; Tieqiang Wu; Huiqing Pan; Youshou Gu; Bin Yang; Yongfeng Chen; Jushi Qiu
Journal:  Acta Derm Venereol       Date:  2010-11       Impact factor: 4.437

3.  CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype.

Authors:  Mirjana Urosevic; Curdin Conrad; Jivko Kamarashev; Kenji Asagoe; Antonio Cozzio; Günter Burg; Reinhard Dummer
Journal:  Hum Pathol       Date:  2005-09       Impact factor: 3.466

4.  Skin lesions in plasmacytoid dendritic cell leukaemia.

Authors:  Annika M Whittle; Martin R Howard
Journal:  Br J Haematol       Date:  2007-11-07       Impact factor: 6.998

5.  Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients.

Authors:  F Julia; T Petrella; M Beylot-Barry; M Bagot; D Lipsker; L Machet; P Joly; O Dereure; M Wetterwald; M d'Incan; F Grange; J Cornillon; G Tertian; E Maubec; P Saiag; S Barete; I Templier; F Aubin; S Dalle
Journal:  Br J Dermatol       Date:  2013-09       Impact factor: 9.302

6.  Blastic plasmacytoid dendritic cell neoplasm in an elderly woman.

Authors:  H B B Foong; M Chong; E M Taylor; J A Carlson; T Petrella
Journal:  Med J Malaysia       Date:  2013-04

Review 7.  Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.

Authors:  J K Chan; V C Sin; K F Wong; C S Ng; W Y Tsang; C H Chan; M M Cheung; W H Lau
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

8.  Clinical and biologic features of CD4(+)CD56(+) malignancies.

Authors:  Jean Feuillard; Marie-Christine Jacob; Françoise Valensi; Marc Maynadié; Rémy Gressin; Laurence Chaperot; Christine Arnoulet; Françoise Brignole-Baudouin; Bernard Drénou; Eliane Duchayne; Annie Falkenrodt; Richard Garand; Emanuelle Homolle; Bernard Husson; Emilienne Kuhlein; Geneviève Le Calvez; Danielle Sainty; Marie-France Sotto; Franck Trimoreau; Marie-Christine Béné
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

10.  Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract.

Authors:  S Nakamura; T Suchi; T Koshikawa; K Kitoh; K Koike; H Komatsu; S Iida; Y Kagami; M Ogura; E Katoh
Journal:  Am J Surg Pathol       Date:  1995-03       Impact factor: 6.394

View more
  2 in total

1.  Blastic plasmacytoid dendritic neoplasm (BPDN) or BPDN-like lesion presenting after influenza vaccination and resolving with topical high potency steroid.

Authors:  Jonathan Yao; Joanna Dong; James Strauchen; Rajendra Singh
Journal:  JAAD Case Rep       Date:  2015-06-13

2.  CT findings associated with blastic plasmacytoid dendritic cell neoplasm: a case report.

Authors:  Daniel Jeong; Jung W Choi; Katherine Jeong; Lubomir Sokol
Journal:  Acta Radiol Open       Date:  2016-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.